I den ene undersøgelse så man på den samlede responsfrekvens for MabThera hos 203 patienter uden reaktion på tidligere behandlinger, og den anden undersøgelse var en vedligeholdelsesundersøgelse med 334 patienter, hvor undersøgelsen varede, indtil sygdommen forværredes.
Two studies looked at MabThera taken alone in patients with follicular lymphoma: one study looked at overall response rate to MabThera in 203 patients who had failed previous treatments and the other study was a maintenance study in 334 patients, looking at the time until the disease got worse.